Results 121 to 130 of about 53,055 (281)

Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses

Biotechnology Progress, EarlyView.
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing, Tomoki Igi, Daniel Strauss   +2 more
wiley   +1 more source

THE ANALYSIS OF THE PHARMACEUTICAL MARKET ON THE EXAMPLE OF MEDICINES OF GROUP OF INHIBITORS OF THE PROTON POMP

Разработка и регистрация лекарственных средств, 2019
In this research is carried out the review of the Russian pharmaceutical market and the comparative characteristic of medicines of group of inhibitors of a proton pomp.
N. V. Mazova, A. L. Marchenko, N. V. Marchenko   +2 more
doaj  

Drug‐Coated Balloon‐Based Strategy for De Novo Coronary Artery Disease Across Complex and High‐Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI).
Dong Oh Kang, Sunwon Kim, Ae‐Young Her, Eun‐Seok Shin   +3 more
wiley   +1 more source

Edaravone for the Treatment of Motor Neurone Disease: A Critical Review of Approved and Alternative Formulations against a Proposed Quality Target Product Profile

Pharmaceutics
Edaravone is one of two main drugs for treating motor neurone disease (MND). This review proposes a specific quality target product profile (QTPP) for edaravone following an appraisal of the issues accounting for the poor clinical uptake of the approved ...
Riuna O’Neill, Okhee Yoo, Philip Burcham, Lee Yong Lim   +3 more
doaj   +1 more source

Final 2‐Year Results of the REFORM Study: A Randomized Trial of Biolimus DCB Versus Paclitaxel DCB for In‐Stent Restenosis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In the REFORM trial, treatment of coronary in‐stent restenosis with a Biolimus A9™ drug‐coated balloon (BCB) was found to be inferior with respect to in‐segment percentage stenosis at 6‐months in comparison to treatment with a standard paclitaxel coated paclitaxel‐coated balloon (PCB). Aims In this manuscript, the final prespecified
Daniel O'Callaghan, J. J. Coughlan, Fernando Alfonso, Joo‐Yong Hahn, Manel Sabate, Ralph Toelg, Samuel Copt, Sean Fitzgerald, Marie‐Claude Morice, Jasper Trevelyan, Darren Mylotte, Antonio Fernandez Ortiz, Rory Durand, Jochen Wöhrle, Franz Xever Kleber, Giuilo Stefanini, Himanshu Rai, Peter O'Kane, Robert A. Byrne   +18 more
wiley   +1 more source

Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review [PDF]

Studies of active drug/excipient compatibility represent an important phase in the preformulation stage of the development of all dosage forms. The potential physical and chemical interactions between drugs and excipients can affect the chemical nature ...
Sandip B. Bharate, Amrita N. Bajaj, Sonali S. Bharate   +2 more
core   +1 more source

Interaction and compatibility studies of efavirenz with pharmaceutical excipients [PDF]

, 2014
Although excipients have traditionally been thought of as being inert, experience has showed interaction between them and the drugs; therefore, is very useful the knowledge about potential physical and chemical interactions.
Araya-Sibaja, Andrea Mariela, Campos, Carlos Eduardo Maduro, Silva, Marco Antônio Segatto, Pereira, Rafael Nicolay, Rocha, Helvécio Vinícius Antunes, Fandaruff, Cinira, Hoffmeister, Cristiane Rodrigues Drago, Cuffini, Silvia Lucia   +7 more
core  

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Using chitosan and xanthan gum mixtures as excipients in controlled release formulations of ambroxol HCl - in vitro drug release and swelling behavior [PDF]

, 2016
Directly compressed matrices were produced using a binary mixture of different chitosan (CH) and xanthan gum (XG) ratios. These hydrophilic excipients were used to control the release of ambroxol HCl. CH and XG were investigated at three ratios of 1:1, 1:
Faisal Al-Akayleh, Mayyas Al Remawi, Mutaz S. Salemc, Adnan Badwan   +3 more
core